1Cromheecke M,Jong KP,Hoekstra HJ.Current treatment for colorectal cancer metastatic to liver.Eur J Surg Oncol,1999,25(5):451-463.
2Tellez C,Benson AB,Lyster MT,et al.Phahe Ⅱ trial of chemoembolization for the treatment to metastatic colorectal carcinoma to the liver and review of the literature.Cancer,1998,82(7):1250-1259.
3Rafaelsen SR.Kronborg O,Larsen C,etal.Intraoperative ultrasonography in detection of hepatic metastases from colorectal cancer.Dis Colon Rectum,1995,38(4):355.
4Fong Y,Fortner J,Sun RL,Brennan MF,Blumgart LH.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases.Ann Surg,1999,230:309-318.
6Sheiner PA,Brower ST.Treatment of metastatic cancer to the liver.Seminars in Liver Disease,1994;14(2):169.
7Bismuth H,Adam R,Levi F,etal.Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Ann Surg,1996;224(4):509-520.
8Meric F,Patt YZ,Curley SA,Chase J,et al.Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy.Ann Surg Oncol,2000,7:490-495.
9Cromheecke M,Jong KP,Hoekstra HJ.Current treatment for colorectal metastatic to the liver.Eur J Surg Oncol,1999,25(5):451-463.
10Freyer G,Rougier P,Bugat R,etal.Prognostic factors for tumor response,progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan(CPT-11) as second-line chemotherapy after 5-Fufailure.CPT-11 F205,F220,F221 and V222 study groups.Br J Cancer,2000,83:431-437.
2[1]Weber SM, Jarnagin WR, DeMatteo RP, et al. Survival after resection of multiple hepatic colorectal metsases[J]. Ann Surg Oncol, 2000,7(9):643-650.
3[2]Asbun HJ, Hugher KS. Management of recurrent and metastatic colorectal carcinoma[J]. Surg Clin North Am, 1993,73(1):145-166.
4[3]Schiltz PM, Beutel LD, Nayak SK, et al. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer[J]. J Immunother, 1997,20(5):377-386.
5[4]Pockaj BA, Sherry RM, Wei JP, et al. Localization of indium labeled TIL to tumor in patient receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response[J]. Cancer,1994,73(6):1731-1737.
6[5]Ikarashi H, Fujita K, Takakuwa K, et al. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes[J]. Cancer Res, 1994,54(1):190-196.
7[6]Kradin RL, Lazarus DS, Dubinett SM, et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer[J]. Lancet,1989,18(1):577-580.
8[7]Bukowski RM, Sharfman W, Murthy S, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma[J]. Cancer Res, 1991,51(16):4199-4205.
